Accelerate to discover

Back to filter

Related topics

In-vivo webinar: a versatile use of SPECT/CT in the development of theranostic tracers

MOLECUBES

Mar 9, 2022

Combining (preclinical) imaging and targeted therapy, is the basis of theranostics. In this webinar, Dr. Florea will...

Curiox webinar: Laminar Wash enables single-cell multiomics and cell hashing

Curiox

Oct 11, 2021

Professor Mats Bemark’s lab at the University of Gothenburg in Sweden studies how the immune system responds to...

May 22, 2022

Blood-Brain Barrier (BBB) - Pathophysiology in ischemic stroke

RWD

Aug 27, 2021

In-depth Understanding of Blood-Brain Barrier (BBB)

Micro-CT user meeting 2021

Bruker Biospin

Aug 19, 2021

Year after year, the Micro-CT User meeting showcases state-of-the-art applications in both life and material sciences,...

Predicting single-cell gene expression with imaging flow cytometry data and machine learning

Luminex

Aug 10, 2021

High-content imaging and single-cell genomics are two of the most prominent high-throughput technologies for studying...

May 22, 2022

Recorded Webinar – the basics of Intravital Fluorescence Microscopy

IVIM Technology

Aug 6, 2021

This is the first of a 4-part series introducing Scintica’s newly formed relationship with IVIM Technology and their...

Show all topics (10)

Monitoring cancer treatments with immuno-PET webinar

Mar 8, 2019

The clinical use of full-length mAbs as imaging agents can be challenging, due to their long biological half-life and relatively slow tumor penetration, which may affect tumor-to-background contrast at early time points. To circumvent these issues, Dr Gabriela Kramer-Marek’s team has developed radiolabeled affibody-based PET tracers that still have high specificity and affinity of the potential therapeutic mAb, but their molecular weight below 60 kDa allows for rapid renal clearance and elimination. In this webinar, Dr Gabriela Kramer-Marek will focus on HER-specific imaging radioconjugates that could provide unique information as cancer biomarkers, including quantification of receptor heterogeneity and early detection of changes in target expression in response to therapy.

Dr Ali Asgar Attarwala, Bruker BioSpin and Dr Gabriela Kramer-Marek, Team Leader Preclinical Molecular Imaging, The Institute of Cancer Research London 

Register Now

Webinar

Related technologies: PET, SPECT, CT

Get more info

Miroslav Vecheta

Support specialist

Miroslav

Vecheta

+420 255 700 886

Send Message

Brand profile

Bruker Biospin

Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.

Related products

Albira combines PET, SPECT and CT imaging in a unique and extremely powerful way

show detail

High Performance Total Body PET and CT for mice & rats with fast scan times with unparalleled quality

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey